MDxHealth SA (MDXH.BR) Stock Overview
Europe - EBR:MDXH - BE0974461940 - Common Stock
MDXH.BR Key Statistics, Chart & Performance
The current stock price of MDXH.BR is 3.02 EUR. In the past month the price increased by 5.19%. In the past year, price increased by 381.66%.
MDXH.BR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 21.47 | 346.25B | ||
| 1ABBV.MI | ABBVIE INC | 21.34 | 344.13B | ||
| AMG.DE | AMGEN INC | 13.5 | 136.74B | ||
| GIS.DE | GILEAD SCIENCES INC | 15.46 | 128.15B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 25.27 | 94.65B | ||
| 1REGN.MI | REGENERON PHARMACEUTICALS | 12.65 | 52.80B | ||
| 1AE.DE | ARGENX SE | 94.63 | 43.41B | ||
| ARGX.BR | ARGENX SE | 94.23 | 43.22B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.77B | ||
| IDP.DE | BIOGEN INC | 9.22 | 18.66B | ||
| 1BIIB.MI | BIOGEN INC | 8.98 | 18.18B | ||
| 1NBIX.MI | NEUROCRINE BIOSCIENCES INC | 41.11 | 11.91B |
Related stock screener links
About MDXH.BR
Company Profile
MDxHealth SA is a BE-based company operating in Biotechnology industry. The company is headquartered in Herstal, Liege and currently employs 258 full-time employees. The company went IPO on 2006-06-26. MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Company Info
MDxHealth SA
CAP Business Center, Rue d'Abhooz 31
Herstal LIEGE BE
Employees: 258
Phone: 3243642070
MDxHealth SA / MDXH.BR FAQ
Can you describe the business of MDxHealth SA?
MDxHealth SA is a BE-based company operating in Biotechnology industry. The company is headquartered in Herstal, Liege and currently employs 258 full-time employees. The company went IPO on 2006-06-26. MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
What is the current price of MDXH stock?
The current stock price of MDXH.BR is 3.02 EUR. The price decreased by -3.76% in the last trading session.
What is the dividend status of MDxHealth SA?
MDXH.BR does not pay a dividend.
How is the ChartMill rating for MDxHealth SA?
MDXH.BR has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is MDXH.BR stock listed?
MDXH.BR stock is listed on the Euronext Brussels exchange.
What sector and industry does MDxHealth SA belong to?
MDxHealth SA (MDXH.BR) operates in the Health Care sector and the Biotechnology industry.
MDXH.BR Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to MDXH.BR. When comparing the yearly performance of all stocks, MDXH.BR is one of the better performing stocks in the market, outperforming 99.77% of all stocks.
MDXH.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MDXH.BR. Both the profitability and financial health of MDXH.BR have multiple concerns.
MDXH.BR Financial Highlights
Over the last trailing twelve months MDXH.BR reported a non-GAAP Earnings per Share(EPS) of -1.68. The EPS decreased by -16.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.61% | ||
| ROE | -393.48% | ||
| Debt/Equity | 2.17 |
MDXH.BR Forecast & Estimates
9 analysts have analysed MDXH.BR and the average price target is 8.4 EUR. This implies a price increase of 178.05% is expected in the next year compared to the current price of 3.02.
For the next year, analysts expect an EPS growth of -6519.8% and a revenue growth 84.81% for MDXH.BR